Phesgo
Active substance: PERTUZUMAB, TRASTUZUMAB, HYALURONIDASE (HUMAN RECOMBINANT)
INJECTION, SOLUTION · PERTUZUMAB 1200 mg/15mL, TRASTUZUMAB 600 mg/15mL, HYALURONIDASE (HUMAN RECOMBINANT) 30000 U/15mL
United StatesActive
Marketing holder: Genentech, Inc.
Verified 2026-10-09 · openFDA NDC
Analogues in other countries- Source: openFDA NDC
- Countries with the substance registered: 3
- PERTUZUMAB · 1200 mg/15mL
- TRASTUZUMAB · 600 mg/15mL
- HYALURONIDASE (HUMAN RECOMBINANT) · 30000 U/15mL
Showing products with this active substance, combinations included; the full composition is shown for each product.
| Country | Products |
|---|---|
| RU 7 |
|
| EU 4 |
Control by country
- Russiaprescription only
Source: GRLS (Russian state register) · record 01a120c3-4abb-7595-aa15-2e6c2d9d03be,01a120c3-b042-7150-940d-05bc1c510f6f,01a120c3-d38a-7ce7-95ba-6cdbfa2316bb,01a120c5-0ba3-7060-88df-afd647364da8;count=4 · valid from 2026-10-09 · verified 2026-10-09
- United Statesprescription only
Source: openFDA NDC · record 01a1208d-306b-773e-b8cf-599d494647eb;count=1 · valid from 2026-10-09 · verified 2026-10-09
- Registration number
- 50242-245
- Registration status
- Active
- Dispensing
- Prescription only
- Route
- SUBCUTANEOUS
- product · openFDA NDC · 50242-245 · Verified 2026-10-09 · open in source
- registration_status · openFDA NDC · 50242-245 · Verified 2026-10-09 · open in source
- ingredients.0 · openFDA NDC · 50242-245 · Verified 2026-10-09 · open in source
- ingredients.1 · openFDA NDC · 50242-245 · Verified 2026-10-09 · open in source
- ingredients.2 · openFDA NDC · 50242-245 · Verified 2026-10-09 · open in source